maxalt smelt frostþurrkuð tafla 10 mg
n.v. organon* - rizatriptanum benzóat - frostþurrkuð tafla - 10 mg
rizatriptan alvogen (rizatriptan portfarma) munndreifitafla 10 mg
alvogen ehf. - rizatriptanum benzóat - munndreifitafla - 10 mg
rizatriptan alvogen (rizatriptan portfarma) munndreifitafla 5 mg
alvogen ehf. - rizatriptanum benzóat - munndreifitafla - 5 mg
rizatriptan sumar pharma (rizatriptan ratiopharm) munndreifitafla 10 mg
alvogen ehf. - rizatriptanum benzóat - munndreifitafla - 10 mg
biorphen stungulyf, lausn 10 mg/ml
sintetica gmbh - phenylephrinum hýdróklóríð - stungulyf, lausn - 10 mg/ml
biorphen stungulyf/innrennslislyf, lausn 0,1 mg/ml
sintetica gmbh - phenylephrinum hýdróklóríð - stungulyf/innrennslislyf, lausn - 0,1 mg/ml
aerinaze
n.v. organon - desloratadine, pseudophedrine sulfate - rinitis, ofnæmi, árstíðabundin - nasal undirbúningur - einkennameðferð við árstíðabundinni ofnæmiskvef í tengslum við nefstífla.
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
fragmin stungulyf, lausn í áfylltri sprautu með nálarvörn 12.500 and-xa a.e.
pfizer aps - dalteparinum natricum inn - stungulyf, lausn í áfylltri sprautu með nálarvörn - 12.500 and-xa a.e.
fragmin stungulyf, lausn í áfylltri sprautu með nálarvörn 7.500 and-xa a.e.
pfizer aps - dalteparinum natricum inn - stungulyf, lausn í áfylltri sprautu með nálarvörn - 7.500 and-xa a.e.